- Home
- LFVN vs SCLX Comparison
LFVN vs SCLX Comparison
Compare LFVN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- SCLX
- Stock Information
- Founded
- LFVN N/A
- SCLX 2011
- Country
- LFVN United States
- SCLX United States
- Employees
- LFVN N/A
- SCLX N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- LFVN Health Care
- SCLX Health Care
- Exchange
- LFVN Nasdaq
- SCLX Nasdaq
- Market Cap
- LFVN 145.2M
- SCLX 139.3M
- IPO Year
- LFVN N/A
- SCLX N/A
- Fundamental
- Price
- LFVN $6.56
- SCLX $21.30
- Analyst Decision
- LFVN Strong Buy
- SCLX Hold
- Analyst Count
- LFVN 2
- SCLX 1
- Target Price
- LFVN $30.50
- SCLX N/A
- AVG Volume (30 Days)
- LFVN 193.5K
- SCLX 162.6K
- Earning Date
- LFVN 11-04-2025
- SCLX 11-14-2025
- Dividend Yield
- LFVN 2.72%
- SCLX N/A
- EPS Growth
- LFVN 143.91
- SCLX N/A
- EPS
- LFVN 0.78
- SCLX N/A
- Revenue
- LFVN $228,877,000.00
- SCLX $40,360,000.00
- Revenue This Year
- LFVN $6.93
- SCLX $89.26
- Revenue Next Year
- LFVN $1.43
- SCLX $203.95
- P/E Ratio
- LFVN $8.49
- SCLX N/A
- Revenue Growth
- LFVN 16.77
- SCLX N/A
- 52 Week Low
- LFVN $5.98
- SCLX $3.60
- 52 Week High
- LFVN $27.38
- SCLX $34.27
- Technical
- Relative Strength Index (RSI)
- LFVN 34.81
- SCLX 62.46
- Support Level
- LFVN $5.98
- SCLX $15.30
- Resistance Level
- LFVN $7.47
- SCLX $27.00
- Average True Range (ATR)
- LFVN 0.49
- SCLX 2.43
- MACD
- LFVN 0.05
- SCLX 0.47
- Stochastic Oscillator
- LFVN 36.84
- SCLX 58.03
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.